Regeneron Pharmaceuticals Inc Total Liabilities
Regeneron Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Regeneron Pharmaceuticals Inc (REGN) has total liabilities worth $10.02 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Regeneron Pharmaceuticals Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Regeneron Pharmaceuticals Inc (1990–2025)
Total liabilities of Regeneron Pharmaceuticals Inc from 1990 to 2025. This chart illustrates how Regeneron Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore REGN long-term investments to assets to see how much of total assets are deployed in long-term investments.
Regeneron Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Regeneron Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Motorola Solutions Inc
NYSE:MSI
|
USA | $16.55 Billion |
|
Cigna Corp
NYSE:CI
|
USA | $115.91 Billion |
|
BAE SYSTEMS ADR/4 LS-025
F:BSPA
|
Germany | €27.35 Billion |
|
MercadoLibre Inc.
NASDAQ:MELI
|
USA | $39.65 Billion |
|
Caixabank SA
MC:CABK
|
Spain | €632.98 Billion |
|
Illinois Tool Works Inc
NYSE:ITW
|
USA | $13.60 Billion |
|
Norfolk Southern Corporation
NYSE:NSC
|
USA | $29.69 Billion |
|
Petróleo Brasileiro S.A. - Petrobras
SA:PETR3
|
Brazil | R$795.83 Billion |
Liability Composition Analysis (1990–2025)
This chart breaks down Regeneron Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see REGN total asset value.
Liquidity & Leverage Metrics
Regeneron Pharmaceuticals Inc Total Liabilities Ratios Explained
Regeneron Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Regeneron Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Regeneron Pharmaceuticals Inc (1990–2025)
The table below shows the annual total liabilities of Regeneron Pharmaceuticals Inc from 1990 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $9.30 Billion | +10.66% |
| 2024-12-31 | $8.41 Billion | +18.27% |
| 2023-12-31 | $7.11 Billion | +8.50% |
| 2022-12-31 | $6.55 Billion | -1.73% |
| 2021-12-31 | $6.67 Billion | +8.60% |
| 2020-12-31 | $6.14 Billion | +65.20% |
| 2019-12-31 | $3.72 Billion | +24.80% |
| 2018-12-31 | $2.98 Billion | +13.62% |
| 2017-12-31 | $2.62 Billion | +3.80% |
| 2016-12-31 | $2.52 Billion | +29.16% |
| 2015-12-31 | $1.95 Billion | +46.99% |
| 2014-12-31 | $1.33 Billion | +33.09% |
| 2013-12-31 | $998.94 Million | +19.62% |
| 2012-12-31 | $835.11 Million | -0.33% |
| 2011-12-31 | $837.85 Million | +49.19% |
| 2010-12-31 | $561.62 Million | +63.05% |
| 2009-12-31 | $344.44 Million | +37.13% |
| 2008-12-31 | $251.19 Million | -47.23% |
| 2007-12-31 | $475.99 Million | +29.18% |
| 2006-12-31 | $368.47 Million | +19.05% |
| 2005-12-31 | $309.50 Million | +6.52% |
| 2004-12-31 | $290.56 Million | -15.02% |
| 2003-12-31 | $341.91 Million | +39.22% |
| 2002-12-31 | $245.59 Million | +7.23% |
| 2001-12-31 | $229.04 Million | +776.08% |
| 2000-12-31 | $26.14 Million | -4.93% |
| 1999-12-31 | $27.50 Million | +7.00% |
| 1998-12-31 | $25.70 Million | -12.88% |
| 1997-12-31 | $29.50 Million | -3.91% |
| 1996-12-31 | $30.70 Million | +18.53% |
| 1995-12-31 | $25.90 Million | -4.43% |
| 1994-12-31 | $27.10 Million | +41.15% |
| 1993-12-31 | $19.20 Million | +79.44% |
| 1992-12-31 | $10.70 Million | +37.18% |
| 1991-12-31 | $7.80 Million | -40.91% |
| 1990-12-31 | $13.20 Million | -- |
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degenera… Read more